Provided by Tiger Fintech (Singapore) Pte. Ltd.

Onconetix Inc.

0.0543
-0.0052-8.74%
Post-market: 0.0521-0.0022-4.05%19:53 EDT
Volume:2.72M
Turnover:146.84K
Market Cap:789.80K
PE:0.00
High:0.0580
Open:0.0550
Low:0.0520
Close:0.0595
Loading ...

Company Profile

Company Name:
Onconetix Inc.
Exchange:
NASDAQ
Establishment Date:
2018
Employees:
12
Office Location:
201 East Fifth Street,Suite 1900,Cincinnati,Ohio,United States
Zip Code:
45202
Fax:
- -
Introduction:
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.

Directors

Name
Position
Erin Henderson
Chairman,Chief Business Officer
Joseph Hernandez
Chief Executive Officer and Director
Allan L. Shaw
Director
James Sapirstein
Director
Kimberly Murphy
Director
Michael Venerable
Director

Shareholders

Name
Position
Joseph Hernandez
Chief Executive Officer and Director
Jon Garfield
Interim Chief Financial Officer
Erin Henderson
Chairman,Chief Business Officer